To test whether the very low blood and bone marrow volumes available from infants are sufficient to perform cfDNA-based molecular neuroblastoma profiling, we exemplarily employed our established multiplex ddPCR protocols [14,17] to monitor MYCN and ALK status in three patients with body weights ≤ 10 kg and ages at diagnosis below 18 months. This evidence concerns the gene ALK and neuroblastoma.